Skip to main content

Find Clinical Trials

Home
Conditions
Hematologic Diseases

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,397 public trials 2,851 recruiting studies

Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Completed

Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients

NCT01010880

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Department of Hematology and Bone Marrow Transplantation,Rambam Medical Center Haifa, Israel

Chaim Sheba Medical Center,Tel-Hashomer Ramat Gan, Israel

View Trial Details

Completed

Two Cycles of PAD Combination by AHCT in MM

NCT01370434

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Asan Medical Center Seoul, Asanbyeongwon-gil, Songpa-gu, South Korea

View Trial Details

Completed

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

NCT00210834

Conditions: Anemia, Hematologic Diseases, Hemic and Lymphatic Diseases
Locations: Not specified

View Trial Details

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

NCT00337948

Conditions: Anemia, Cancer, Chemotherapy, +3 more
Locations: Not specified

View Trial Details

Completed

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

NCT00341055

Conditions: Anemia, Cancer, Chemotherapy, +3 more
Locations: Not specified

View Trial Details

Completed

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

NCT00210600

Conditions: Anemia, Hematologic Diseases, Hemic and Lymphatic Diseases
Locations: Not specified

View Trial Details

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

NCT00338416

Conditions: Anemia, Cancer, Hematologic Diseases, +2 more
Locations: Not specified

View Trial Details

Completed

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

NCT00210587

Conditions: Anemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +1 more
Locations: Not specified

View Trial Details

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

NCT00269984

Conditions: Anemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +1 more
Locations: Not specified

View Trial Details

Completed

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

NCT00091910

Conditions: Anemia, Hematologic Diseases, Hemic and Lymphatic Diseases
Locations: Not specified

View Trial Details